ArticleTranslational oncology2025
PRDM1 promotes the stemness of gastric cancer cells by enhancing the transactivation of Myc.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reading the tumour at single-cell resolution: Original research in the Precision Therapeutics special issue.Translational oncology · 2026Article
- Double jeopardy: howFrontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe roles of transcriptional factor PR/SET domain 1 (PRDM1) have been revealed in numerous tumor types. However, its effects on gastric cancer progression are still confusing. This study aimed to explore the roles and underlying mechanisms of PRDM1 in gastric cancer progression.
methodsIn silico analysis was used to analyze gene expression levels, expression correlation, and the relationship with patients' survivals. Functional experiments, including Western blot, RT-qPCR, sphere-formation ability, cytometry analysis, and tumorigenic analysis, were conducted to evaluate PRDM1's effects on gastric cancer stemness. ChIP, luciferase reporter, and bioinformatic analysis were performed to reveal the underlying mechanisms.
resultswe demonstrated that PRDM1 was highly expressed in gastric cancer tissues and cells. Knockdown of PRDM1 significantly attenuated gastric cancer stemness. Mechanistical studies indicated that PRDM1 directly bound to the promoter region of Myc, a critical contributor of cancer stem cells (CSCs), and thus enhanced Myc transcription activity.
conclusionsTaken together, this study indicates that PRDM1 could enhance gastric cancer stemness by increasing the transcriptional activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.